Daniel Flora

2.9k total citations
8 papers, 109 citations indexed

About

Daniel Flora is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Daniel Flora has authored 8 papers receiving a total of 109 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 2 papers in Molecular Biology and 2 papers in Genetics. Recurrent topics in Daniel Flora's work include Estrogen and related hormone effects (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Treatment and Pharmacology (2 papers). Daniel Flora is often cited by papers focused on Estrogen and related hormone effects (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Treatment and Pharmacology (2 papers). Daniel Flora collaborates with scholars based in United States, France and Spain. Daniel Flora's co-authors include Christopher Dakhil, Nguyet Le‐Lindqwister, Charles L. Loprinzi, Stephanie S. Faubion, Thomas J. Smith, Paul J. Novotny, Roberto A. Leon‐Ferre, Eric Wolfe, Kathryn J. Ruddy and Mark L. Graham and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Daniel Flora

8 papers receiving 106 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Flora United States	4	70	35	34	23	20	8	109
H. Al-Eid Saudi Arabia	3	65 0.9×	13 0.4×	14 0.4×	15 0.7×	20 1.0×	3	125
Kristin A. Rand United States	5	34 0.5×	35 1.0×	6 0.2×	22 1.0×	52 2.6×	6	145
Ludovica Grassi Italy	5	40 0.6×	15 0.4×	53 1.6×	32 1.4×	16 0.8×	12	167
Julyann Pérez‐Mayoral Puerto Rico	7	71 1.0×	65 1.9×	8 0.2×	50 2.2×	5 0.3×	13	172
Κωνσταντίνος Αγιαννιτόπουλος Greece	7	27 0.4×	20 0.6×	7 0.2×	12 0.5×	21 1.1×	20	156
Goska Leslie United Kingdom	4	44 0.6×	56 1.6×	4 0.1×	13 0.6×	39 1.9×	7	117
Amit Agarwal India	6	40 0.6×	46 1.3×	4 0.1×	9 0.4×	8 0.4×	20	109
Donatella Grasso Italy	9	107 1.5×	13 0.4×	4 0.1×	7 0.3×	40 2.0×	22	159
Lisa Richters Germany	6	42 0.6×	16 0.5×	3 0.1×	17 0.7×	8 0.4×	13	129
J. Merschdorf Poland	2	103 1.5×	34 1.0×	4 0.1×	11 0.5×	34 1.7×	2	156

Countries citing papers authored by Daniel Flora

Since Specialization

Citations

This map shows the geographic impact of Daniel Flora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Flora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Flora more than expected).

Fields of papers citing papers by Daniel Flora

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Flora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Flora. The network helps show where Daniel Flora may publish in the future.

Co-authorship network of co-authors of Daniel Flora

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Flora. A scholar is included among the top collaborators of Daniel Flora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Flora. Daniel Flora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Bear, Harry D., Dipankar Bandyopadhyay, Michael O. Idowu, et al.. (2024). Abstract PO1-18-04: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2- breast cancer (NCT02957968). Cancer Research. 84(9_Supplement). PO1–18. 2 indexed citations

Patel, Reema, Ari David Baron, Brian C. Boulmay, et al.. (2024). BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology. 42(3_suppl). 1 indexed citations

Kolesar, Jill, Donglin Yan, Zhonglin Hao, et al.. (2023). Abstract CT221: Phase II of frontline maintenance rucaparib in combination with nivolumab in ES SCLC. Cancer Research. 83(8_Supplement). CT221–CT221. 1 indexed citations

Wise‐Draper, Trisha M., Aakash Desai, Arielle Elkrief, et al.. (2020). LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis. Annals of Oncology. 31. S1201–S1202. 13 indexed citations

Leon‐Ferre, Roberto A., Paul J. Novotny, Eric Wolfe, et al.. (2019). Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectrum. 4(1). pkz088–pkz088. 52 indexed citations

Flora, Daniel, et al.. (2019). Abstract GS6-02: A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study SC-1603. Cancer Research. 79(4_Supplement). GS6–2. 5 indexed citations

Fogelman, David R., Antonio Cubillo, Pilar García‐Alfonso, et al.. (2018). Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Medicine. 7(11). 5382–5393. 33 indexed citations

Fogelman, David R., Johanna C. Bendell, Antonio Cubillo, et al.. (2017). Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) + regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 35(4_suppl). 663–663. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact